Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Market Cap | 712.398 Million | Shares Outstanding | 144.21 Million | Avg 30-day Volume | 1.972 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.58 |
Price to Revenue | 52.6499 | Debt to Equity | 0.0 | EBITDA | -248.265 Million |
Price to Book Value | 2.2113 | Operating Margin | -664.5847 | Enterprise Value | 1.199 Billion |
Current Ratio | 9.784 | EPS Growth | 0 | Quick Ratio | 9.493 |
1 Yr BETA | 1.5498 | 52-week High/Low | 17.49 / 4.83 | Profit Margin | -667.7362 |
Operating Cash Flow Growth | -60.5762 | Altman Z-Score | 8.4338 | Free Cash Flow to Firm | -224.213 Million |
Earnings Report | 2023-05-03 |
Please sign in first
none
3 Thousand total shares from 1 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
8,358,208 | 2023-03-22 | 1 | |
CHANG DAVID D PRESIDENT AND CEO |
|
6,251,063 | 2023-03-22 | 2 |
SCHMIDT ERIC THOMAS CHIEF FINANCIAL OFFICER |
|
2,015,034 | 2023-03-22 | 2 |
MOORE ALISON CHIEF TECHNICAL OFFICER |
|
672,731 | 2023-03-22 | 2 |
ROBERTS ZACHARY EVP OF R&D |
|
399,943 | 2023-03-22 | 3 |
BHAVNAGRI VEER GENERAL COUNSEL |
|
556,049 | 2023-03-14 | 4 |
AMADO RAFAEL EVP OF R&D |
|
541,946 | 2022-10-07 | 6 |
|
218,271 | 2022-08-11 | 4 | |
|
0 | 2022-07-08 | 2 | |
|
76,986 | 2022-06-15 | 1 | |
|
303,063 | 2022-06-15 | 1 | |
|
191,892 | 2022-06-15 | 1 | |
|
77,605 | 2022-06-15 | 1 | |
|
71,070 | 2022-06-15 | 1 | |
|
0 | 2022-03-31 | 0 | |
|
18,716,306 | 2022-01-12 | 0 | |
|
18,716,306 | 2020-08-06 | 0 | |
|
22,032,040 | 2018-10-15 | 0 | |
|
0 | 2018-10-10 | 0 | |
|
0 | 2018-10-10 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-03-24 20:13:19 -0400 | 2023-03-22 | A | 1,492,200 | a | 1,492,200 | direct | ||||||||||
2023-03-24 20:13:19 -0400 | 2023-03-22 | A | 1,924,464 | a | 4,193,911 | direct | -2.1869 | 0.0 | 1 | -2.1869 | 2 | |||||
2023-03-24 20:14:49 -0400 | 2023-03-22 | A | 994,800 | a | 994,800 | direct | ||||||||||
2023-03-24 20:14:49 -0400 | 2023-03-22 | A | 1,282,976 | a | 1,654,886 | direct | -2.1869 | 0.0 | 1 | -2.1869 | 2 | |||||
2023-03-24 20:16:40 -0400 | 2023-03-22 | A | 148,035 | a | 399,943 | direct | -2.1869 | 0.0 | 1 | -2.1869 | 2 | |||||
2023-03-24 20:17:56 -0400 | 2023-03-22 | A | 432,738 | a | 432,738 | direct | ||||||||||
2023-03-24 20:17:56 -0400 | 2023-03-22 | A | 558,094 | a | 862,439 | direct | -2.1869 | 0.0 | 1 | -2.1869 | 2 | |||||
2023-03-24 20:19:18 -0400 | 2023-03-22 | A | 432,738 | a | 432,738 | direct | ||||||||||
2023-03-24 20:19:18 -0400 | 2023-03-22 | A | 558,094 | a | 672,731 | direct | -2.1869 | 0.0 | 1 | -2.1869 | 2 | |||||
2023-03-16 16:46:11 -0400 | 2023-03-14 | F | 23,628 | $5.67 | d | 556,049 | direct | -2.1858 | -8.561 | 0.0 | 1 | -8.561 | 6 | |||
2023-03-16 16:49:16 -0400 | 2023-03-14 | F | 8,351 | $5.51 | d | 114,637 | direct | -2.1858 | -8.561 | 0.0 | 1 | -8.561 | 6 | |||
2023-03-16 17:08:11 -0400 | 2023-03-14 | F | 35,879 | $5.47 | d | 304,345 | direct | -2.1858 | -8.561 | 0.0 | 1 | -8.561 | 6 | |||
2023-03-16 17:32:26 -0400 | 2023-03-14 | F | 22,340 | $5.56 | d | 2,269,447 | direct | -2.1858 | -8.561 | 0.0 | 1 | -8.561 | 6 | |||
2023-02-14 17:10:36 -0500 | 2023-02-13 | S | 3,000 | $6.85 | d | 577,677 | direct | yes | -3.0429 | -10.2351 | -31.2586 | 0.0 | 1 | -31.9502 | 29 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 22:15:04 UTC | 4.3441 | 0.4759 | 200000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 21:45:05 UTC | 4.3441 | 0.4759 | 200000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 21:15:03 UTC | 4.3441 | 0.4759 | 200000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 20:45:04 UTC | 4.3441 | 0.4759 | 200000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 20:15:04 UTC | 4.4355 | 0.3845 | 100000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 19:45:04 UTC | 4.4355 | 0.3845 | 100000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 19:15:04 UTC | 4.4355 | 0.3845 | 100000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 18:45:04 UTC | 4.4355 | 0.3845 | 100000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 18:15:04 UTC | 4.4355 | 0.3845 | 100000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 17:45:04 UTC | 4.4355 | 0.3845 | 100000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 17:15:03 UTC | 4.4355 | 0.3845 | 100000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 16:45:04 UTC | 4.4355 | 0.3845 | 100000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 16:15:04 UTC | 4.4355 | 0.3845 | 100000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 15:45:04 UTC | 4.4355 | 0.3845 | 100000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 15:15:03 UTC | 4.4355 | 0.3845 | 100000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 14:45:04 UTC | 4.4355 | 0.3845 | 100000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 14:15:04 UTC | 4.4355 | 0.3845 | 100000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 13:45:03 UTC | 4.4355 | 0.3845 | 100000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 13:15:03 UTC | 4.4355 | 0.3845 | 100000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-03-31 12:45:03 UTC | 4.4355 | 0.3845 | 100000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund | ALLO | -87.0 shares, $-3280.77 | 2020-09-30 | N-PORT |
FundVantage Trust- Gotham Defensive Long Fund | ALLO | -80.0 shares, $-1555.2 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Master Neutral Fund | ALLO | -44.0 shares, $-1659.24 | 2020-09-30 | N-PORT |
FundVantage Trust- Gotham Index Plus All-Cap Fund | ALLO | -161.0 shares, $-3129.84 | 2020-03-31 | N-PORT |
Trust for Professional Managers- Convergence Long/Short Equity Fund | ALLO | -2326.0 shares, $-43007.74 | 2021-11-30 | N-PORT |
RBB Fund, Inc.- Boston Partners Long/Short Research Fund | ALLO | -71985.0 shares, $-709772.1 | 2022-11-30 | N-PORT |
FundVantage Trust- Gotham Hedged Plus Fund | ALLO | -1016.0 shares, $-6390.64 | 2022-12-30 | N-PORT |